home / stock / bmea / bmea message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $BMEA morning dip S30.4 BO32.5 does it push HH | znewcar1 | investorshangout | 03/30/2023 2:16:47 PM |
znewcar1: $BMEA 99% v18,2M c30.71 f29,396M H31.54 First Post! Big day gap chop N go it 29.47 then di | znewcar1 | investorshangout | 03/28/2023 8:31:17 PM |
$BMEA: Whether or not my 'BANK' is collapsing | Invest-in-America | investorshub | 03/28/2023 8:31:11 PM |
$BMEA: And I'll bet that YOU, Boss, grabbed | Invest-in-America | investorshub | 03/28/2023 5:19:46 PM |
https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fus | TheFinalCD | investorshub | 03/28/2023 5:13:06 PM |
$BMEA: Glad I grabbed a BIG CHUNK of | Invest-in-America | investorshub | 03/28/2023 2:08:00 PM |
$BMEA has a price target of $37.00 per | Bbradley8 | investorshub | 01/31/2023 11:04:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Biomea Fusion Inc. Company Name:
BMEA Stock Symbol:
NASDAQ Market:
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of be...
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. After just a 4-week treatment period in type 2 diabetes patients, who had previ...